Marksans Pharma recalls Metformin ER Tablets over probable carcinogen
Metformin extended release tablets are indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus
New Delhi: Marksans Pharma on Monday said it is recalling 11,279 bottles of diabetes drug Metformin extended release tablets due to presence of cancer causing contaminant.
The company has issued a voluntary recall of one batch of Metformin extended release tablets (USP 500 mg) due to detection of NDMA (N-nitrosodimethylamine), Marksans Pharma said in a regulatory filing.
The recalled batch contains 11,279 bottles, it added. Metformin extended release tablets are indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.
Read also: 5 firms told to recall Metformin for high levels of probable carcinogen
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd